Vensana Capital recently announced closing a $425 million Fund III for continued investment in innovative medtech companies.
The Edina, Minnesota–based venture capital firm said yesterday that it now has roughly $1 billion in capital under management.
The news of Vensana Capital’s fundraise should provide some good news in a medtech fundraising environment that is a mixed bag, even as exits through mergers and acquisitions and even IPOs appear to be picking up. (DeviceTalks Editorial Director Tom Salemi will hold a DeviceTalks Tuesday webinar with HSBC Managing Director Jonathan Norris at 12 p.m. Eastern time on Jan. 23, 2025 to discuss this year’s medtech funding environment. Click here to register for the free webinar.)
Since its founding in 2019 by Kirk Nielsen and Dr. Justin Klein, Vensana Capital has partnered with more than 20 companies and seen six exits totaling nearly $3 billion in value. Exits included the acquisitions of Artelon (by Stryker), Intact Vascular (by Philips), Personal Genome Diagnostics, Relievant Medsystems (by Boston Scientific), and Vesper Medical (by Philips), as well as the initial public offering of CVRx.
“We are incredibly proud of the progress Vensana has made since launch as we work tirelessly to build the leading medtech investment and company building platform, and we are beyond grateful for the continued strong support of our limited partners,” said Nielsen, a managing partner of Vensana Capital, said in a news release.
Klein, also a managing partner, said: “Our entire team is excited about the opportunity ahead as we continue to partner with entrepreneurs who are transforming healthcare with breakthrough innovations in medical technology. We approach each day mindful of the impact that our work has on the missions of our limited partners, on our portfolio companies and their teams, and — most importantly — on our clinician partners and their patients.”
Leave a Reply